Glioblastoma

Patient: Join a Trial Investigator: Open a Trial

Glioblastoma Cancer Clinical Trial

Glioblastoma (GBM) is an aggressive and frequently lethal brain malignancy, which is usually resistant to conventional therapies and immunotherapies. GBM has an incidence of two to three per 100,000 adults per year, and accounts for 52 percent of all primary brain tumors.

We are currently developing a protocol to treat recurrent glioblastoma using Aldoxorubicin and our Anktiva.

Dr. Patrick Soon-Shiong
Executive Chairman, ImmunityBio

This unique approach to orchestrating the innate and adaptive immune systems to induce immunogenic cell death may be an important new approach for pancreatic cancer patients—these being among the most challenging to treat with poor prognosis.

Recent Research

QUILT-88: NANT Pancreatic Cancer Vaccine –Trial in Progress Open-label, randomized, comparative phase2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer

Jun 4, 2021

Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with Checkpoint Inhibitors (CPI)

Jun 4, 2021

See All Research

Recent News

FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer

Jun 15, 2021

Open-label Phase 1b/2 study will evaluate the safety and preliminary efficacy of Anktiva (N-803) and PD-L1 t-haNK in combination with antibody-drug conjugate Trodelvy and low-dose chemotherapy in subjects with advanced triple-negative breast cancer (TNBC) after prior...

ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients

Jun 10, 2021

Sponsored by the NIAID and AIDS Clinical Trials Group, an “HIV cure study” will evaluate whether IL-15 superagonist AnktivaÔ (N-803) alone or together with broadly neutralizing antibodies can control HIV following interruption of antiretroviral therapy (ART). The...

See All News

How Can ImmunityBio Help You?

Solutions for Patients

Many therapies for treating cancer and infectious diseases severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Learn More

Opportunities for Trial Investigators

Natural killer cell-based immunotherapies are key to future cancer treatments. Our investigational NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.

Learn More

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

Learn More

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

About Us